CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis

• Main Authors: Jeroen FJ Bogie (Author), Elien Grajchen (Author), Elien Wouters (Author), Bieke Broux (Author), Piet Stinissen (Author), Bart Van Wijmeersch (Author), Jerome JA Hendriks (Author)
• Format: Book
• Published: SAGE Publishing, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and aims: Alemtuzumab is a humanized monoclonal antibody that depletes CD52-bearing B and T lymphocytes. Clinical trials defined that systemic administration of alemtuzumab reduces disease severity in the relapsing-remitting phase of multiple sclerosis (MS). However, its efficacy in progr...